Increase in Net Income
Net income increased to $0.54 per diluted share in Q2 2025 from $0.40 per diluted share in Q2 2024, driven by an increase in interest income.
Interest Income Growth
Interest income rose by $4.6 million to $22.8 million in Q2 2025 from $18.2 million in Q2 2024, primarily due to increased income from investments.
Decrease in Interest Expense
Interest expense decreased by $700,000 in Q2 2025 compared to the same period in the prior year, attributed to deleveraging efforts.
Stabilized Occupancy Rate Improvement
The national stabilized occupancy rate improved to 94.6% in July, with demand outperforming expectations in the first half of the year.
Life Science Lease Agreement
A 245,000 square foot lease was secured with an AI biologics company, producing a debt yield of just over 8% for the Alewife project.
Low Leverage Profile
The company maintains a low leverage profile, providing various capital options to pursue accretive growth.